€81.60
-1.20 (-1.45%)
EUR · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where PHN.MI is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
7 interventional
government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Effect of a Food for Special Medical Purposes on Muscle Mass Preservation During GLP-1 RAs Weight Loss TreatmentNCT07393360Change in Appendicular Skeletal Muscle Mass (ASMM)Randomized · Quadruple-masked · Supportive care | Not applicable | Recruiting | Dietary supplement: Myosave® · Other: Placebo | Obesity & Overweight | 144 | Dec 2026 | ≤ 133 d | 2026-03-23 |
| Oral Supplementation With a Formulation Based on Cetylated Fatty Acids for Post-fracture Long Bone HealingNCT07299851Radiographic Assessment of Callus Formation using the modified Radiographic Union Score for Tibia (mRUST).Randomized · Triple-masked · Treatment | Not applicable | Recruiting | Dietary supplement: CFA-based food supplement · Other: Placebo | Fracture Femur, Fracture Tibia | 100 | May 2026 | — | 2025-12-23 |
| Efficacy and Tolerability of Sucrosomial® Iron vs Ferric Maltol in Iron Deficient WomenNCT07308769Hemoglobin normalization at week 12Randomized · Open-label · Treatment | Phase 4 | Recruiting | Dietary supplement: Sucrosomial® Iron (Sideral® Forte) · Drug: Ferric Maltol (Feraccru®) | Anemia, Iron Deficiency Anemia (IDA) | 146 | May 2026 | — | 2026-03-23 |
| Wide Spectrum Micronutrients Supplementation in Patients With Cancer Related Fatigue During Neoadjuvant and Adjuvant ChemotherapyNCT06137833The change of fatigue perception by the patient through the BFI questionnaireRandomized · Triple-masked · Supportive care | Not applicable | Recruiting | Dietary supplement: APPOPRTAL® · Other: Placebo | Fatigue, Breast Cancer | 92 | 2025-12-31 | — | 2025-10-01 |
| Effect of a Topical Cetylated Fatty Acid Cream on Pain Relief in Patients With Knee OsteoarthritisNCT07745387Change from Baseline in Walking Arthritis Pain Intensity Score (VAS)Randomized · Quadruple-masked · Treatment | Not applicable | Completed | Other: Cetilar® Cream, Placebo cream | Knee Osteoarthristis | 156 | 2024-11-20actual | — | 2026-08-04 |
| CETI-ANKLE: Cetilar®️ in Patients With Ankle Injury or Chronic Trauma to the AnkleNCT06137820Change From Baseline in FAAM (Foot and Ankle Ability and Measure) total score questionnaire on day 30Randomized · Single-masked · Treatment | Not applicable | Unknown status | Device: Cetilar® (topical cream), Cetilar Placebo | Ankle Injury or Chronic Trauma to the Ankle | 80 | 2023-08-19actual | — | 2023-11-18 |
| LIKEST Study: Lipocet® in Adults With Primary Knee Osteoarthritis Grade 3-4NCT06134115Change From Baseline in Pain on the Visual Analogue Scale (VAS scale) on day 60Randomized · Single-masked · Treatment | Not applicable | Completed | Dietary supplement: Lipocet® (food supplement), Lipocet Placebo | Primary Knee Osteoarthritis Grade 3 - 4 | 60 | 2023-03-06actual | — | 2023-11-18 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19